36 search results for: chronic inflammation

Overview of Type 2 <b>Inflammation</b> in the Presentations of AD, PN, and CSU

expert video

Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU

2 min

Dermatology

Dr. Eric Simpson summarizes the role of type 2 inflammation in the clinical manifestations of AD, PN, and CSU.

IRS-ISIAN 2024 | Targeting Type 2 <b>Inflammation</b>: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

expert video

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

9 min

Rhinology

Prof. Joaquim Mullol reports on biologic improvements in sense of smell and nasal congestion in patients with and without a history of endoscopic sinus surgery.

Type 2 <b>Inflammation</b> and Neuroimmune Axis Dysregulation in AD, PN, and CSU

expert video

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

3 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

Contribution of Type 2 Cytokines to <b>Inflammation</b> and Itch in AD, PN, and CSU

expert video

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU

3 min

Dermatology

Dr. Marta Ferrer describes the roles of type 2 cytokines in the processes involved in AD, PN, and CSU pathogenesis.

How Does Protective Type 2 Immunity Become Harmful Type 2 <b>Inflammation</b>?

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

expert video

ESPGHAN 2024 | Burden and Timely Recognition of Pediatric EoE

13 min

Gastroenterology

Dr. Dhandapani Ashok discusses patient and caregiver burden in pediatric EoE and the challenges with identifying EoE in a young patient population.

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and <b>Inflammation</b>

expert video

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

10 min

Rhinology

Prof. Joaquim Mullol examines the mechanisms of smell loss in CRSwNP including the roles of conductive and sensorineural dysfunction.

Podcast

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

20 min

Dermatology

Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.

Infographic

Blood Eosinophils: A Biomarker in COPD

14 min

Pulmonology

In COPD, blood eosinophil testing is one of the five core assessments for initial patient evaluation, according to the GOLD Report. This infographic illustrates the role that blood eosinophils, as a biomarker for type 2 inflammation, play in predicting exacerbation risk and other COPD outcomes, and provides information from the GOLD Report on when to test for blood eosinophils and how eosinophils may guide patient management.

expert video

EAACI 2022 | Hard to Swallow: Identifying and Managing EoE in the Allergy Clinic

21 min

Gastroenterology

Experts Prof. Ingrid Terreehorst and Prof. Arjan Bredenoord discuss the allergist’s perspective on identifying and management of patients with EoE.

expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

16 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: LebanonChange country/region